retatrutide mechanism glp-1 gip glucagon triple agonist Why target one pathway when you can master three? 🎯 ​Introducing Reta-HUB® (Retatrutide) — The GIP/ GLP-1/ that's setting a new standard in metabolic care. ​Developed exclusively for physicians Beyond GLP-1: Retatrutide's triple-agonist mechanism
Description
doi: 10.1111/bjd.12886
It says the class numbers at least 100,000 people
One such option is Mounjaro (tirzepatide), a once-weekly injectable medication that was originally approved for type 2 diabetes and is now FDA-approved for weight management in adults with obesity or overweight and at least one weight-related health condition
doi:10.14309/ajg.00000000000003525 65
Diabetes and cognitive impairment: A role for glucotoxicity and dopaminergic dysfunction
